Search

Your search keyword '"Sarcoma, Alveolar Soft Part drug therapy"' showing total 78 results

Search Constraints

Start Over You searched for: Descriptor "Sarcoma, Alveolar Soft Part drug therapy" Remove constraint Descriptor: "Sarcoma, Alveolar Soft Part drug therapy"
78 results on '"Sarcoma, Alveolar Soft Part drug therapy"'

Search Results

1. Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial.

2. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).

3. How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma.

4. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.

5. Mimicking angiogenic microenvironment of alveolar soft-part sarcoma in a microfluidic coculture vasculature chip.

6. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

7. Severe immediate hypersensitivity to gadolinium contrast agent after targeted treatment in a patient with alveolar soft part sarcoma: A case report and review of literature.

8. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).

9. Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

10. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

11. Treatment of a case of primary alveolar soft part sarcoma of the lung: Case report and literature review.

12. Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.

13. Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022.

14. Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disorders.

15. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).

17. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.

18. First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report.

19. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.

20. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.

21. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.

23. Stereotactic radiosurgery as a primary treatment for metastatic skull base alveolar soft part sarcoma: a case report.

24. Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report.

25. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.

26. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma.

27. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.

28. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.

29. Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice.

30. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.

31. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.

32. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).

33. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

34. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.

35. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

36. Alveolar soft part sarcoma metastatic to the breast: a case report.

37. Secondary polycythemia in a sarcoma patient: a commentary about cediranib.

38. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.

39. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

40. Effective treatment of advanced alveolar soft part sarcoma with sunitinib: A case report.

42. Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.

43. Hypopigmented Skin Lesions After Immunotherapy.

44. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.

45. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

46. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

47. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.

48. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.

49. Advanced alveolar soft part sarcoma responds to apatinib.

50. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.

Catalog

Books, media, physical & digital resources